Table 1.
Baseline characteristics
|
FLT3 ITD (n = 39) |
FLT3 TKD (n = 15) |
Total (N = 54) |
|
|---|---|---|---|
| Age, y | |||
| Median (range) | 67.6 (60.3–82.7) | 65.4 (60.8–82.1) | 67.4 (60.3–82.7) |
| ≥70 | 17 (44) | 3 (20) | 20 (37) |
| Sex | |||
| Male | 20 (51) | 10 (67) | 30 (56) |
| Female | 19 (49) | 5 (33) | 24 (44) |
| Onset of AML | |||
| De novo | 32 (82) | 14 (93) | 46 (85) |
| Therapy-related myeloid | 2 (5) | 1 (7) | 3 (6) |
| MDS related | 5 (13) | 0 (0) | 5 (9) |
| ELN classification | |||
| Intermediate I/CN-AML | 21 (54) | 6 (40) | 27 (50) |
| Intermediate II | 12 (31) | 5 (33) | 17 (32) |
| ELN adverse | 1 (3) | 2 (13) | 3 (6) |
| Cytogenetics insufficient for evaluation | 5 (13) | 2 (13) | 7 (13) |
| Allelic ratio | |||
| Median (range) | 0.7 (0.1–7.3) | 0.3 (0.1–2.1) | |
| WBC count | |||
| Median (range) | 22 (0.8–344) | 16 (0.7–60) | 18 (0.7–344) |
| Bone marrow blast, % | |||
| Median (range)* | 68 (0–96) | 58 (31–96) | 60 (0–96) |
| ECOG performance status | |||
| 0 | 18 (46) | 5 (33) | 23 (43) |
| 1 | 17 (44) | 10 (67) | 27 (50) |
| 2 | 4 (10) | 0 | 4 (7) |
Data are presented as n (%) of patients unless otherwise indicated.
CN, cytogenetically normal; ECOG, Eastern Cooperative Oncology Group; ELN, European LeukemiaNet; MDS, myelodysplastic syndrome; WBC, white blood cell.
*
One patient was enrolled with multiple myeloid sarcomas but no increase in bone marrow blasts.